I guess MYL picked up what PFE terminated a similar deal with Biocon last year. Refresh my memory, was ever given a reason by anyone?
No official reason was ever given, to my knowledge. In #msg-73195053, I speculated that PFE was concerned MYL would expand its collaboration with Biocon to include insulin (which turned out to be exactly what happened).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.